DDCB coordinates infrastructure and expertise in the areas of drug discovery and chemical biology and makes it available to the scientific community. The DDCB platform provides services in assay development and chemical screening from medium to high throughput with a broad range of technologies including the DDCB-developed drug sensitivity and resistance testing platform. Our service portfolio also includes antibacterial screening, specialized assays for novel materials, repurposing of drugs, virtual screening, chemoinformatics, as well as open access to a large national chemical collection, translational support and user base education.


Contact details


Prof. Päivi Tammela
paivi.tammela@helsinki.fi


Nodes


Node/Host UniversityNode PI
HiLIFE – FIMM High Throughput Biomedicine Unit (HiLIFE-HTB), UH
Päivi Tammela
paivi.tammela@helsinki.fi
HiLIFE - Faculty of Pharmacy (HiLIFE-PHAR), UH
Henri Xhaard
henri.xhaard@helsinki.fi
Biocenter Kuopio – Drug Design and Synthesis Laboratory (BCK-PMC), UEF
Antti Poso
antti.poso@uef.fi
BioCity Turku – Turku Screening Unit/UTU (BCT-TSU), UTU
Michael Courtney
miccou@utu.fi

UEF: University of Eastern Finland; UH: University of Helsinki; UO: University
of Oulu; UTU: University of Turku; TAU: Tampere University; ÅAU: Åbo
Akademi University.



Services


  • Project and assay guidance and development support – all sites
  • Chemical screening – FIMM and Faculty of Pharmacy, UH, BioCity Turku
  • Drug sensitivity and resistance screening (DSRT) and drug repurposing – FIMM
  • Chemoinformatics, molecular modeling, and virtual screening – Biocenter Kuopio, Faculty of Pharmacy, UH, and BioCity Turku
  • Follow-up screening and testing – all sites
  • Access to a large national chemical collection – FIMM

Image

Recent user publications


Pietiäinen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, Turunen L, Hassinen A, Potdar S, Koponen A, Sebestyen EG, Kovacs F, Kriston A, Hollandi R, Burian K, Terhes G, Visnyovszki A, Fodor E, Lacza Z, Kantele A, Kolehmainen P, Kakkola L, Strandin T, Levanov L, Kallioniemi O, Kemeny L, Julkunen I, Vapalahti O, Buzas K, Paavolainen L, Horvath P, Hepojoki J. Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2. Cell Rep Methods. 2023, 3, 100565. doi: 10.1016/j.crmeth.2023.100565.

Jokinen EM, Niemeläinen M, Kurkinen ST, Lehtonen JV, Lätti S, Postila PA, Pentikäinen OT, Niinivehmas S. Virtual Screening Strategy to Identify Retinoic Acid-Related Orphan Receptor γt Modulators. Molecules. 2023, 28, 3420. doi: 10.3390/molecules28083420

Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype. ChemMedChem. 2022, e202200161. doi: 10.1002/cmdc.202200161

Malani D, Kumar A, Bruck O, Kontro M, Yadav B, Hellesoy M, Kuusanmaki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Vastrik I, Kivinen K, Saarela J, Raty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discovery. 2022; 12, 1-14. doi: 10.1158/2159-8290.CD-21-0410.

Mäki-Mikola E, Lauren P, Uema N, Kikuchi K, Takashima Y, Laaksonen T, Lajunen T. Establishing a simple perfusion cell culture system for light-activated liposomes. Sci Rep. 2023, 13, 2050. doi: 10.1038/s41598-023-29215-6


Image
Image
Image